Vertex Pharmaceuticals Incorporated (VRTX) slips on deep earnings
Vertex Pharmaceuticals Incorporated (VRTX) slips after a narrow EPS miss, but the deeper read is more nuanced: revenue beat estimates, net income stayed solid, and the cystic fibrosis franchise continued to anchor results. This analysis goes beyond the headline to examine product mix, quarterly trends, and market reaction.
Vertex Pharmaceuticals Incorporated (VRTX) fell 1.34% after reporting quarterly EPS of $4.73, just below the $4.74 consensus, even as revenue beat expectations at $3.33 billion versus $3.23 billion. The mixed print suggests investors are still rewarding top-line growth, but want stronger earnings conversion before bidding the stock higher. For investors, the takeaway is that Vertex remains fundamentally strong, but near-term upside may depend on execution beyond its core cystic fibrosis franchise.
Vertex Pharmaceuticals Incorporated (VRTX) slips after earnings
Vertex Pharmaceuticals Incorporated (VRTX) slipped 1.34% to $470.72 after quarterly EPS came in at $4.73, just below the $4.74 consensus. Revenue told a better story, reaching $3.33B versus $3.23B expected, but the mixed print gave investors little reason to reward the stock in the latest regular session. Volume was 1,447,762 shares, below the 1,553,964 average.
Key Takeaways
VRTX earnings produced a narrow EPS miss at $4.73 versus $4.74 expected, while revenue beat consensus at $3.33B versus $3.23B.
Revenue reached $3.33B for the June quarter, above $2.99B in March and $3.23B in December.
TRIKAFTA/KAFTRIO remained Vertex's largest disclosed product line, generating $10.3127B in 2025 revenue versus $10.2386B in 2024.
The latest quarterly financials list net income of $1.10B, compared with $1.03B in March and $1.19B in December.
The latest regular-session close fell to $470.72, with trading volume below its average, signaling a restrained immediate response rather than a sharp capitulation.
Analyst sentiment remains constructive, with 47 Buy ratings, 8 Holds, and 1 Sell rating in the listed consensus.
The central message from this Vertex Pharmaceuticals Incorporated earnings analysis is simple: revenue execution was stronger than expected, but EPS did not clear the bar. The company reported $3.33B in revenue against a $3.23B estimate. By contrast, EPS reached $4.73 against a $4.74 estimate.
The revenue figure also extended the recent quarterly scale. Vertex reported $2.99B for the quarter ended March 31, $3.23B for the quarter ended December 31, $3.08B for September, and $2.96B for June 2025. The June 2026 result therefore stands above each of those prior quarterly revenue figures.
Net income reached $1.10B in the June quarter. The prior quarterly figures were $1.03B in March, $1.19B in December, $1.08B in September, and $1.03B in June 2025. That pattern shows a profitable business with earnings moving alongside product mix and quarterly timing.
EPS history adds useful perspective. The earnings surprise record shows $4.47 for the May 4, 2026 report, $5.03 for February 12, $4.80 for November 3, 2025, and $4.52 for August 4, 2025. The latest $4.73 result sits above the May and August figures, but below the February peak.
Vertex's disclosed product mix remains heavily concentrated in cystic fibrosis therapies. TRIKAFTA/KAFTRIO produced $10.3127B in 2025 revenue. ALYFTREK generated $837.8M, while Manufactured Product, Other contributed $820.1M. The 2024 figures included $10.2386B from TRIKAFTA/KAFTRIO and $781.5M from Manufactured Product, Other.
That mix matters because the company is using its established CF franchise to finance a broader product portfolio. On the first-quarter 2026 earnings call, CEO Reshma Kewalramani said total product revenue reached $2.99B, reflecting 8% growth year over year. She also said newer disease areas contributed approximately 25% of total product revenue growth.
"Vertex Pharmaceuticals Incorporated is off to a terrific start in 2026, which we see as a year defined by execution." - Reshma Kewalramani, CEO and President, Vertex Pharmaceuticals Incorporated, Q1 2026 Earnings Call
Kewalramani's comments point to the strategic tension behind the latest VRTX earnings: the mature CF franchise still supplies scale, while newer products must carry more of the growth narrative. The company identified ALYFTREK, KASJEVY, GERNAVICS, Povi, and enaxaplin as part of that expansion.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
VRTX closed at $470.72, down 1.34% in the latest regular session. Volume of 1,447,762 shares was below the 1,553,964 average. That combination points to a measured reaction to the EPS miss, rather than the heavy selling that often follows a major earnings failure.
The analyst consensus remains Buy. It includes 47 Buy ratings, 8 Holds, and 1 Sell, with no Strong Buy or Strong Sell ratings listed. The distribution is constructive, although the narrow EPS miss gives cautious analysts a clear reason to focus on earnings conversion rather than revenue alone.
Recent named analyst actions also show a wide range of views. Barclays maintained an Overweight rating and a $615 target on May 6, 2026. Morgan Stanley maintained Overweight with a $616 target, while Bernstein maintained Outperform with a $572 target and RBC Capital maintained Outperform with a $543 target. Canaccord Genuity maintained Hold with a $436 target.
Earlier actions were similarly mixed. Maxim Group upgraded VRTX to Buy from Hold on March 18, 2026, with a $575 target. Leerink Partners downgraded the stock on May 6, 2025 and cut its target from $550 to $503. The current consensus and these target levels show confidence in Vertex's franchise, but also a meaningful debate over how quickly its newer products can add to the CF base.
The market's reaction fits that debate. Revenue exceeded consensus, but EPS did not. For a biotechnology company valued at $119.5B, a revenue beat must translate into durable earnings growth before investors treat it as a complete win. Markets have a particular talent for grading the one decimal place that missed.
The first-quarter VRTX earnings call supplied the clearest strategic detail around Vertex's pipeline. Kewalramani described Povi as a potential best-in-class BAFF/APRIL inhibitor after interim Phase III RAINIER data in IgA nephropathy showed a 52% reduction from baseline in proteinuria and a 49.8% reduction versus placebo.
"The interim analysis results from the Phase III RAINIER study in IgAN on efficacy and safety from top to bottom were sparkling and further fueled our enthusiasm for Povi as a potentially best-in-class BAFF/APRIL inhibitor." - Reshma Kewalramani, CEO and President, Vertex Pharmaceuticals Incorporated, Q1 2026 Earnings Call
Vertex also reported that the Povi primary membranous nephropathy Phase II portion had completed enrollment and that the Phase III portion had started. The company said its enaxaplin AMPLITUDE study remained on track for an interim analysis in early 2027. These milestones give the pipeline a defined sequence, even though they do not change the reported quarter's EPS.
The CF pipeline contains both expansion and pruning. Vertex said label expansions for ALYFTREK and TRIKAFTA could cover about 95% of people with CF, including patients with rare genotypes. It also said the VX-828 next-generation CFTR study remained on track for results in the second half of 2026.
"If it is possible to do better in CF, we are committed to being the ones who do so." - Reshma Kewalramani, CEO and President, Vertex Pharmaceuticals Incorporated, Q1 2026 Earnings Call
At the same time, Vertex discontinued VX-522 after tolerability issues persisted despite actions taken in the trial. Kewalramani said the company would not assess the program's efficacy or full safety because of the early termination. That decision removes one research avenue, but it also shows management willing to stop a program that failed to clear a safety hurdle.
"Despite actions we have taken in the trial to overcome these issues, we have not been able to do so, and as such, we have chosen to discontinue the program." - Reshma Kewalramani, CEO and President, Vertex Pharmaceuticals Incorporated, Q1 2026 Earnings Call
Bottom Line
VRTX earnings delivered a revenue beat but missed EPS by a narrow margin, and the stock slipped despite Vertex's $3.33B quarterly sales. The $119.5B company still has a powerful CF base, while Povi, KASJEVY, GERNAVICS, and enaxaplin provide the next growth tests. For investors, the central issue is whether new products can turn strong revenue execution into consistent earnings upside.
+Why did Vertex Pharmaceuticals stock fall after earnings?
Vertex Pharmaceuticals Incorporated (VRTX) slipped 1.34% to $470.72 after quarterly EPS came in at $4.73, narrowly missing the $4.74 consensus. Revenue beat expectations at $3.33 billion versus $3.23 billion, but the small earnings miss limited the market's reaction.
+Did Vertex beat revenue and miss earnings in the latest quarter?
Yes. Vertex reported revenue of $3.33 billion, above the $3.23 billion consensus, while EPS came in at $4.73 versus $4.74 expected. The result was a mixed earnings print rather than a clear beat or miss.
+What was Vertex's biggest product line in 2025?
TRIKAFTA/KAFTRIO was Vertex's largest disclosed product line, generating $10.3127 billion in 2025 revenue. That compares with $10.2386 billion in 2024, showing the franchise remains the company's core revenue engine.
+What is Wall Street's current view on Vertex stock?
The listed analyst consensus remains constructive, with 47 Buy ratings, 8 Holds, and 1 Sell. Recent target prices from major firms such as Barclays, Morgan Stanley, Bernstein, and RBC Capital were all well above the latest close of $470.72.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on VRTX?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
